Seismic Therapeutic Closes $121M Series B Financing
Summary
Led by Jo Viney, PhD, Founder, President and CEO, Seismic Therapeutic is a biotechnology company working on how immunology therapies are discovered and developed, enabled by machine learning. It has a growing preclinical stage and biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. Proceeds from the Series B financing will be used to advance through Phase 1 proof-of-mechanism trials with Seismic’s two lead programs: a pan‑immunoglobulin (Ig) G protease sculpting (Sc) enzyme candidate (S-1117) and a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody candidate (S-4321). In addition, the Series B will enable the continued growth of the company’s pipeline in both the IgSc and DcB product areas, beyond the lead programs. The funding will also enable the company to further expand its proprietary machine learning-enabled IMPACT platform with the development and implementation of additional methods to enhance biologics drug discovery in immunology.